1 completed, 1 terminated, 1 unknown. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 1, Terminated 1, Unknown 1 |
Follow Vicus Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer VT-122, Placebo - Prostatic Neoplasms | Phase 2 | Terminated | Vicus Therapeutics | 35 | 2013-06-01 | 2018-04-26 |
| Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC) Sorafenib, VT-122 (propranolol plus etodolac), Placebo - HCC | Phase 2 | Unknown | Vicus Therapeutics | 20 | 2010-12-01 | 2015-12-09 |
| Regimen for the Treatment of Cachexia in Subjects With NSCLC VT-122 low dose, VT-122 high dose - Cachexia | Phase 2 | Completed | Vicus Therapeutics | 37 | 2007-01-01 | 2013-01-30 |
Anorexia (1) · Cachexia (1) · Prostatic Neoplasms (1)
Etodolac (2) · Propranolol (2) · Sorafenib (1)
United States (3) · India (1)